Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP8 | P22894 | 4/20 | 0.42 |
| ▸ | MMP3 | P08254 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 5/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070617 | 0.99 | MMP1 (0.40) | MMP1MMP2MMP8MMP3CYP3A4 | |
| SCHEMBL7070620 | 0.99 | MMP1 (0.40) | MMP1MMP2MMP8MMP3CYP3A4 | |
| SCHEMBL7068831 | 0.87 | MMP1 (0.52) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL7068829 | 0.87 | MMP1 (0.52) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL7065490 | 0.84 | DPP4 (0.44) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL7068722 | 0.84 | ALDH1A1 (0.45) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL7068719 | 0.84 | ALDH1A1 (0.45) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL7065488 | 0.84 | DPP4 (0.44) | MMP1MMP2MMP8MMP3APP | |
| SCHEMBL6956005 | 0.83 | GAA (0.44) | MMP1MMP2MMP8MMP3CHRM1 | |
| SCHEMBL6956004 | 0.83 | GAA (0.44) | MMP1MMP2MMP8MMP3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MMP1 4360/4885MMP2 3975/4885MMP8 4818/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | MMP1 4360/4885MMP2 3975/4885MMP8 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.